Literature DB >> 20495297

Immunomodulatory effect of Eriobotrya japonica seed extract on allergic dermatitis rats.

Guangchen Sun1, Yingqin Liu, Jinling Zhu, Miki Iguchi, Saburo Yoshioka, Mitsuhiko Miyamura, Shojiro Kyotani.   

Abstract

We examined the immunomodulatory effect of Eriobotrya japonica seed extract (ESE) on rat allergic dermatitis elicited by repeated dinitrofluorobenzene (DNFB) application on the ear. Oral administration of ESE significantly inhibited development of allergic dermatitis based on lower ear thickness and serum immunoglobulin E (IgE) levels. Th1 cytokine interferon-gamma (IFN-gamma) and interleukin-2 (IL-2), Th2 cytokine interleukin-4 (IL-4) and interleukin-10 (IL-10) in the lesional skin were determined. Oral administration of ESE significantly decreased IL-4 while significantly increasing IL-10 in lesional skin, and the lower levels of IFN-gamma and IL-2 were reversed by oral administration of ESE. The infiltration of eosinophils in the lesional skin was decreased by oral administration of ESE. These results suggested that ESE exerts anti-allergic actions by improving the balance of Th1/Th2 in allergic dermatitis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20495297     DOI: 10.3177/jnsv.56.145

Source DB:  PubMed          Journal:  J Nutr Sci Vitaminol (Tokyo)        ISSN: 0301-4800            Impact factor:   2.000


  3 in total

Review 1.  Chinese medicines reported to have effects on contact dermatitis in the last 20 years.

Authors:  Youngchul Jung; Byungju Kim; Mi Heon Ryu; Hyungwoo Kim
Journal:  Chin J Integr Med       Date:  2017-03-02       Impact factor: 1.978

Review 2.  Biological Activities of Extracts from Loquat (Eriobotrya japonica Lindl.): A Review.

Authors:  Yilong Liu; Wenna Zhang; Changjie Xu; Xian Li
Journal:  Int J Mol Sci       Date:  2016-12-06       Impact factor: 5.923

3.  The Anti-Inflammatory Effect of Fructus Kochiae on Allergic Contact Dermatitis Rats via pERK1/2/TLR4/NF-κB Pathway Activation.

Authors:  Zuoqi Xiao; Suxi Xiao; Yongning Zhang; Tao Pan; Bo Ouyang
Journal:  Evid Based Complement Alternat Med       Date:  2018-01-04       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.